Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.

Volltext-Artikel, E-Books und Literaturhinweise aus dem EBSCO Discovery Service

"Artikel & mehr" berücksichtigt nur einen Teil der für die Bibliothek der Frankfurt UAS verfügbaren Datenbanken. Zur Übersicht in DBIS

Ergebnis verändern

einschränken: Volltextzugriff; Academic (peer-reviewed) journals
erweitern: Auch Volltexte der Artikel durchsuchen; Verwandte Themen suchen

Publikationstyp

Thema

erschienen in

Verlag

Geographic terms

Sprache

Datenbank

Erscheinungsjahr

Von:

Bis:

Treffer 1 - 25 von 1561, Suchdauer: 0.66s

12 3 4 5 6 7 8 9 10 11 weiter »

1
Olaparib in HR-deficient, metastatic triple-negative breast and platinum-sensitive relapsed ovarian cancers without germline mutations in BRCA1/2: phase 2 EMBRACE trial

von Sjoquist, Katrin M. ; Dobrovic, Alexander ; Robledo, Kristy P. ; et al.

British Journal of Cancer. :1-12
- Zum Volltext (via ReDI)
Merkliste

2
No prognostic role for FIGO grading in mismatch repair deficient endometrial carcinoma

von Wakkerman, Famke C. ; Post, Cathalijne C.B. ; Ørtoft, Gitte ; et al.

In European Journal of Cancer 26 August 2026 244
- View full text via DOI
Merkliste

3
Desert Immune Phenotype in Endometrial Carcinoma: A Distinct Subgroup With Poor Prognosis and Targetable Mutations

von Kaya, Merve ; Lin, Lawrence H. ; Oosting, Jan ; et al.

In Modern Pathology June 2026 39(6)
- View full text via DOI
Merkliste

4
Solving unknown primary cancer with earlier diagnosis - the SUPER-ED trial: study protocol for a stepped-wedge cluster randomised controlled trial to support earlier diagnosis for people presenting with malignancy of undefined primary origin

von Ugalde, Anna ; Tothill, Richard W. ; Quinn, Stephen ; et al.

BMC Cancer. 25(1)
- Zum Volltext in PubMed Central
Merkliste

5
Whole genome sequencing improves tissue-of-origin diagnosis and treatment options for cancer of unknown primary

von Rebello, Richard J. ; Posner, Atara ; Dong, Ruining ; et al.

Nature Communications. 16(1)
- Zum Volltext in PubMed Central
Merkliste

6
Pragmatic gynecologic cancer clinical trials: statements and roadmap from the Gynecologic Cancer InterGroup Chicago Brainstorming Meeting

von Madariaga, Ainhoa ; Veneziani, Ana ; Bookman, Michael ; et al.

In International Journal of Gynecological Cancer September 2026 36(9)
- View full text via DOI
Merkliste

7
Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial

von Lorusso, Domenica ; Gladieff, Laurence ; O'Malley, David M ; et al.

In The Lancet 18-24 April 2026 407(10538):1513-1524
- View full text via DOI
Merkliste

8
Survival and patterns of failure in small cell neuroendocrine carcinoma of the cervix treated with definitive chemoradiotherapy

von O’Shea, Julianne ; Yu, Kelvin ; Chang, David ; et al.

In International Journal of Gynecological Cancer February 2026 36(2)
- View full text via DOI
Merkliste

9
Adverse event profile following maintenance olaparib in patients with BRCA-mutated platinum-sensitive relapsed serous ovarian cancer in the phase III SOLO2 trial

von Ledermann, Jonathan A. ; Lortholary, Alain ; Penson, Richard T. ; et al.

In International Journal of Gynecological Cancer February 2026
- View full text via DOI
Merkliste

10
Impact of age and comorbidity on safety outcomes in phase 1 trial participants for metastatic solid malignancies

von Shahnam, Adel ; Hitchen, Nadia ; Manoharan, Sathya ; et al.

In Journal of Geriatric Oncology November 2025 16(8)
- View full text via DOI
Merkliste

11
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trial

von Post, Cathalijne C B ; de Boer, Stephanie M ; Powell, Melanie E ; et al.

In The Lancet Oncology October 2025 26(10):1370-1381
- View full text via DOI
Merkliste

12
Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial

von Olawaiye, Alexander B ; Gladieff, Laurence ; O'Malley, David M ; et al.

In The Lancet 21-27 June 2025 405(10496):2205-2216
- View full text via DOI
Merkliste

13
Phase 2b, open-label, single-arm, multicenter pilot study of the efficacy, safety, and tolerability of dostarlimab in women with early-stage mismatch repair-deficient endometrioid endometrial adenocarcinoma

von Obermair, Andreas ; Gebski, Val ; Goh, Jeffrey ; et al.

In International Journal of Gynecological Cancer April 2025 35(4)
- View full text via DOI
Merkliste

14
Pembrolizumab in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) and non–MSI-H/non–dMMR advanced endometrial cancer: Phase 2 KEYNOTE-158 study results

von O'Malley, David M. ; Bariani, Giovani M. ; Cassier, Philippe A. ; et al.

In Gynecologic Oncology February 2025 193:130-135
- View full text via DOI
Merkliste

15
PARP inhibition with rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancers

von Kristeleit, Rebecca ; Leary, Alexandra ; Oaknin, Ana ; et al.

British Journal of Cancer. 131(5):820-831
- Zum Volltext in PubMed Central
Merkliste

16
Prediction of recurrence risk in endometrial cancer with multimodal deep learning

von Volinsky-Fremond, Sarah ; Horeweg, Nanda ; Andani, Sonali ; et al.

Nature Medicine. 30(7):1962-1973
- Volltextverfügbarkeit prüfen (via ReDI)
Merkliste

17
Clinical research in endometrial cancer: consensus recommendations from the Gynecologic Cancer InterGroup

von Barretina-Ginesta, Pilar ; Bennett, Katherine ; Berek, Jonathan ; et al.

In The Lancet Oncology September 2024 25(9):e420-e431
- View full text via DOI
Merkliste

18
Prognostic impact and causality of age on oncological outcomes in women with endometrial cancer: a multimethod analysis of the randomised PORTEC-1, PORTEC-2, and PORTEC-3 trials

von Wakkerman, Famke C ; Wu, Jiqing ; Putter, Hein ; et al.

In The Lancet Oncology June 2024 25(6):779-789
- View full text via DOI
Merkliste

19
Cell-free DNA in plasma and ascites as a biomarker of bevacizumab response- a translational research sub-study of the REZOLVE (ANZGOG-1101) clinical trial

von Werner, Bonnita ; Sjoquist, Katrin M ; Espinoza, David ; et al.

In Translational Oncology May 2024 43
- View full text via DOI
Merkliste

20
Molecular and Clinicopathologic Characterization of Mismatch Repair-Deficient Endometrial Carcinoma Not Related to MLH1 Promoter Hypermethylation

von Kaya, Merve ; Post, Cathalijne C.B. ; Tops, Carli M. ; et al.

In Modern Pathology March 2024 37(3)
- View full text via DOI
Merkliste

21
Unravelling mutational signatures with plasma circulating tumour DNA

von Hollizeck, Sebastian ; Wang, Ning ; Wong, Stephen Q. ; et al.

Nature Communications. 15(1)
- Zum Volltext in PubMed Central
Merkliste

22
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3):10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trial

von Post,Cathalijne C.B. ; de Boer,Stephanie M. ; Powell,Melanie E. ; et al.

Schlagworte: Oncology
- View full text via BASE
Merkliste

23
Clinical and Molecular Characteristics of High-Risk, Recurrent, or Metastatic Endometrial Cancer That Is Human Epidermal Growth Factor Receptor 2-Low

von Van Dijk,Dione ; Vermij,Lisa ; León-Castillo,Alicia ; et al.

Schlagworte: Taverne; Oncology; Cancer Research
- View full text via BASE
Merkliste

24
Cancer of the corpus uteri: A 2025 update

von Koskas, Martin ; Crosbie, Emma J. ; Fokdal, Lars ; et al.

International Journal of Gynecology & Obstetrics ; volume 171, issue S1, page 60-77 ; ISSN 0020-7292 1879-3479
- View full text via BASE
Merkliste

25
Modified study designs to expand treatment options in personalised oncology: a multistakeholder view

von Le Tourneau, Christophe ; André, Fabrice ; Helland, Åslaug ; et al.

In European Journal of Cancer November 2023 194
- View full text via DOI
Merkliste

12 3 4 5 6 7 8 9 10 11 weiter »

Sie haben nicht gefunden, wonach Sie gesucht haben? Diese Services können Ihnen weiterhelfen.
Hilfe & Kontakt ǀ Fernleihe | Hilfe zur Fernleihe ǀ Literaturvorschlag| Literaturvorschlag